(Q37417760)

20 August 2017

1 reference

title

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials (English)

1 reference

interstitial lung disease

20 August 2017

main subject

1 reference

Karen Au

1

1 reference

20 August 2017

Dinesh Khanna

2

1 reference

20 August 2017

Philip J Clements

3

1 reference

20 August 2017

Daniel E Furst

4

1 reference

20 August 2017

Donald P Tashkin

5

1 reference

20 August 2017

publication date

1 April 2009

1 reference

Current Rheumatology Reports

20 August 2017

published in

1 reference

20 August 2017

volume

11

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

111-119

1 reference

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-009-0016-2

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-009-0016-2

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-009-0016-2

Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-009-0016-2

Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-009-0016-2

Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts.

21 January 2018

1 reference

12 December 2020

Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis

1 reference

12 December 2020

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study

1 reference

12 December 2020

Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease

1 reference

12 December 2020

Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

1 reference

12 December 2020

Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions

1 reference

12 December 2020

Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease

1 reference

12 December 2020

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

12 December 2020

Cytokine directed therapy in scleroderma: rationale, current status, and the future

1 reference

12 December 2020

Experience with azathioprine in systemic sclerosis associated with interstitial lung disease

1 reference

12 December 2020

Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells

1 reference

12 December 2020

Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

1 reference

12 December 2020

Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases

1 reference

12 December 2020

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study

1 reference

12 December 2020

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

1 reference

12 December 2020

Usual interstitial pneumonia.

1 reference

12 December 2020

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

1 reference

12 December 2020

The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma

1 reference

12 December 2020

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

1 reference

12 December 2020

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease

1 reference

12 December 2020

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

1 reference

12 December 2020

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

1 reference

12 December 2020

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

12 December 2020

IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells

1 reference

12 December 2020

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

1 reference

12 December 2020

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

1 reference

12 December 2020

Imatinib as a novel therapeutic approach for fibrotic disorders

1 reference

12 December 2020

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

1 reference

12 December 2020

Changes in causes of death in systemic sclerosis, 1972-2002

1 reference

12 December 2020

Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.

1 reference

12 December 2020

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

1 reference

12 December 2020

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

1 reference

12 December 2020

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

1 reference

12 December 2020

Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases

1 reference

12 December 2020

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

1 reference

12 December 2020

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

1 reference

12 December 2020

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

1 reference

12 December 2020

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

1 reference

12 December 2020

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease

1 reference

12 December 2020

Interstitial lung disease in systemic sclerosis: a simple staging system

1 reference

12 December 2020

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

12 December 2020

Effect of cyclosporine, mycophenolate mofetil, and their combination with steroids on apoptosis in a human cultured monocytic U937 cell line

1 reference

12 December 2020

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

1 reference

12 December 2020

Severe restrictive lung disease in systemic sclerosis.

1 reference

12 December 2020

Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung

1 reference

12 December 2020

Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis

1 reference

12 December 2020

Cyclophosphamide for scleroderma lung disease

1 reference

12 December 2020

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

12 December 2020

Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma

1 reference

12 December 2020

A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease

1 reference

12 December 2020

Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement

1 reference

12 December 2020

High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease

1 reference

12 December 2020

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

12 December 2020

Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis.

1 reference

12 December 2020

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

1 reference

12 December 2020

10.1007/S11926-009-0016-2

Identifiers

DOI

1 reference

20 August 2017

1 reference